SMMT Share Price Performance
Recent SMMT News & Updates
No updates
Summit Therapeutics Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.32
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Summit Therapeutics Inc. Competitors
About SMMT
- Founded
- 2003
- Employees
- 159
- CEO
- WebsiteView website
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 10.1%
- 1 Year: 17.7%
- Year to Date: 5.9%
The market has dropped by 18% in the last 7 days, with the Financials sector leading declines. As for the longer term, the market has actually risen by 18% in the last year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading